FDA's outside experts to review GSK, AstraZeneca drugs; Biotech gives very early positive indications for cell therapy
GSK’s much-awaited anemia drug for patients with chronic kidney disease will be assessed by FDA’s outside experts.
The agency’s cardiovascular and renal drugs advisory committee …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
